Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...

Bibliografski detalji
Glavni autori:	Alton, E, Beekman, J, Boyd, A, Brand, J, Carlon, M, Connolly, M, Chan, M, Conlon, S, Davidson, H, Davies, J, Davies, L, Dekkers, J, Doherty, A, Gea-Sorli, S, Gill, D, Griesenbach, U, Hasegawa, M, Higgins, T, Hironaka, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Innes, J, Maher, T, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Schmidt, A, Stevenson, B, Sumner-Jones, S, Toshner, R, Tsugumine, S, Wasowicz, M, Zhu, J
Format:	Journal article
Jezik:	English
Izdano:	BMJ Publishing Group 2016

Slični predmeti

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
od: Griesenbach, U, i dr.
Izdano: (2016)

Moving lentiviral-based gene therapy into a first-in-man CF trial
od: Griesenbach, D, i dr.
Izdano: (2015)

Towards a first-in-human trial with a pseudotyped lentivirus
od: Alton, EW, i dr.
Izdano: (2020)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
od: Hyde, S, i dr.
Izdano: (2015)

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
od: Griesenbach, U, i dr.
Izdano: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
od: Griesenbach, U, i dr.
Izdano: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
od: Griesenbach, U, i dr.
Izdano: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
od: Alton, E, i dr.
Izdano: (2014)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
od: Alton, E, i dr.
Izdano: (2014)

Lentivirus gene therapy for autoimmune pulmonary alveolar proteinosis
od: Palau, H, i dr.
Izdano: (2019)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
od: Paul-Smith, M, i dr.
Izdano: (2017)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
od: Alton, E, i dr.
Izdano: (2012)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
od: Alton, E, i dr.
Izdano: (2012)

Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
od: Lund-Palau, H, i dr.
Izdano: (2018)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
od: Paul-Smith, M, i dr.
Izdano: (2018)

Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis
od: Lund-Palau, H, i dr.
Izdano: (2018)

Recombinant Sendai virus vector to evaluate vector distribution in a large animal model of lung gene transfer
od: McLachlan, G, i dr.
Izdano: (2004)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
od: Pytel, K, i dr.
Izdano: (2016)

Development of an immunocytochemical assay to detect human CFTR expression following gene therapy
od: Davidson, H, i dr.
Izdano: (2008)

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
od: McLachlan, G, i dr.
Izdano: (2011)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
od: Griesenbach, U, i dr.
Izdano: (2011)

Caprine lentivirus in sheep milk and semen
od: C.C.V. Lima, i dr.

An immunocytochemical assay to detect human CFTR expression following gene transfer.
od: Davidson, H, i dr.
Izdano: (2009)

Low levels of CFTR gene transfer with F/HN pseudotyped lentivirus are sufficient to generate ion transport correction in airway cell cultures from cystic fibrosis patients
od: Sergijenko, A, i dr.
Izdano: (2020)

Genetic medicines for CF: Hype versus reality
od: Alton, E, i dr.
Izdano: (2016)

A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution.
od: Gifford, R, i dr.
Izdano: (2008)

OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
od: Sumner-Jones, S, i dr.
Izdano: (2009)

Gene therapy for respiratory diseases; progress and a changing context
od: Alton, EWFW, i dr.
Izdano: (2020)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
od: Gill, DR, i dr.
Izdano: (2010)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep
od: Alton, E, i dr.
Izdano: (2013)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
od: Alton, E, i dr.
Izdano: (2013)

Discovery and analysis of the first endogenous lentivirus
od: Katzourakis, A, i dr.
Izdano: (2007)

Discovery and analysis of the first endogenous lentivirus.
od: Katzourakis, A, i dr.
Izdano: (2007)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
od: Davies, J, i dr.
Izdano: (2009)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
od: Davies, J, i dr.
Izdano: (2009)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
od: Davies, G, i dr.
Izdano: (2011)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
od: Davies, J, i dr.
Izdano: (2011)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
od: Alton, E, i dr.
Izdano: (2013)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
od: Alton, E, i dr.
Izdano: (2012)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
od: Alton, E, i dr.
Izdano: (2013)